Effect of Treatment with Nasal lgA on the Incidence of Infectious Disease in World-Class Canoeists

Earlier studies of endurance athletes have shown decreased levels of secretory lgA and an increased frequency of upper respirataory tract (URT) infections after periods of hard training. In this study, 14 world-class canoeists were studied during very hard physical training, after lower-intensity training combined with 17 days of treatment with nasal lgA, and during low intensity training off-season. The ELISA method was used to determine lgA in nasopharyngeal (nph) secretions and saliva (s). The results demonstrated unchanged nph secretions before, during and after lgA treatment (IgAbulin, Immuno AG, Vienna, Austria). Saliva lg-A increased significantly from a median value of 147 μg/ml (range 37 - 634) to 410 μg/ml (range 82 - 974) (p < 0.05) during treatment. Thereafter, s-lgA decreased to 244 μg/ml (range 85 - 689) off-season. A control group of untrained students showed similar nph IgA to that of the elite canoeists. The athletes receiving nasal IgA showed no signs of URT and were considered healthy during 14.5 days out of 17 days of treatment as compared to 12.3 healthy days out of 17 days in the control group. In summary there was no significant decrease in lgA in untreated elite canoeists as compared to untrained controls. Nasal lgA treatment increased the lgA level in saliva only, but no significant decrease in URT symptoms was seen during the lgA treatment period.

Key words

Athletes - infection - IgA - immunoglobulin - treatment - nasopharynx